Tp53 Signature Predicts The Efficacy Of Neoadjuvant Chemotherapy (Nac) Of Breast Cancers

Background: We have reported that status of the TP53 mutation is predictable by expression profile of 33 genes (TP53 signature) in breast cancer and that the TP53 signature can predict overall survival and recurrent free survival of early breast cancer (Cancer Sci. 99: 324-32, 2008). The aim of this study is to determine whether the TP53 signature can also predict both the efficacy of NAC and the recurrence after surgery in breast cancer.